Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,432.97
(
1.08%
)
US TECH 100
28,510.40
(
-0.05%
)
Dow Jones
50,009.35
(
1.31%
)
Brent Oil
103.41
(
1.10%
)
Bitcoin
77,190.76
(
-0.38%
)
News Focus
News Focus
Post# of 326
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122993
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 08/08/2019 4:25:02 PM

Thursday, August 08, 2019 4:25:02 PM

Post# of 326
Hmm…

https://finance.yahoo.com/news/nektar-therapeutics-reports-financial-results-201500243.html

Nektar is hosting a conference call with analysts and investors today on which it will discuss quarterly results. On the call, the company will provide a specific update and discussion on its bempegaldesleukin clinical development program, including recent developments related to the manufacturing of bempegaldesleukin.

Bempegaldesleukin is f/k/a NKTR-214.

The stock is currently halted. CC at 5pm ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NKTR News
More NKTR News